Anagliptin

Systematic (IUPAC) name
	N-[2-[[2-[(2S)-2-Cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
Clinical data
Trade names	Suiny
Legal status	Approved in Japan;
Routes of; administration	Oral
Identifiers
CAS Number	739366-20-2
ATC code	none
ChemSpider	28492667
Chemical data
Formula	C19H25N7O2
Molecular mass	383.45 g/mol
	SMILES CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N ;
	InChI InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1 ; Key:LDXYBEHACFJIEL-HNNXBMFYSA-N ;

Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan.^[1] It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".^[2]

References

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.